214 related articles for article (PubMed ID: 16448522)
1. Double-blind, randomized, multicentre study of the efficacy and safety of gliclazide-modified release in the treatment of Chinese type 2 diabetic patients.
Lu CH; Chang CC; Chuang LM; Wang CY; Jiang YD; Wu HP
Diabetes Obes Metab; 2006 Mar; 8(2):184-91. PubMed ID: 16448522
[TBL] [Abstract][Full Text] [Related]
2. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients.
Schernthaner G; Grimaldi A; Di Mario U; Drzewoski J; Kempler P; Kvapil M; Novials A; Rottiers R; Rutten GE; Shaw KM
Eur J Clin Invest; 2004 Aug; 34(8):535-42. PubMed ID: 15305887
[TBL] [Abstract][Full Text] [Related]
3. Gliclazide modified release.
McGavin JK; Perry CM; Goa KL
Drugs; 2002; 62(9):1357-64; discussion 1365-6. PubMed ID: 12076188
[TBL] [Abstract][Full Text] [Related]
4. Gliclazide modified release: results of a 2-year study in patients with type 2 diabetes.
Drouin P; Standl E;
Diabetes Obes Metab; 2004 Nov; 6(6):414-21. PubMed ID: 15479217
[TBL] [Abstract][Full Text] [Related]
5. Glargine insulin/gliclazide MR combination therapy is more effective than premixed insulin monotherapy in Chinese patients with type 2 diabetes inadequately controlled on oral antidiabetic drugs.
Zhou J; Zheng F; Guo X; Yang H; Zhang M; Tian H; Guo L; Li Q; Mo Y; Jia W
Diabetes Metab Res Rev; 2015 Oct; 31(7):725-33. PubMed ID: 25952634
[TBL] [Abstract][Full Text] [Related]
6. Diamicron MR once daily is effective and well tolerated in type 2 diabetes: a double-blind, randomized, multinational study.
Drouin P
J Diabetes Complications; 2000; 14(4):185-91. PubMed ID: 11004426
[TBL] [Abstract][Full Text] [Related]
7. NIDDM: new once-daily intervention for type 2 diabetes mellitus: Diaprel MR.
Ionescu-Tîrgovişte C; Gavrilă L; Brădescu OM; Guja C
Rom J Intern Med; 2004; 42(2):431-40. PubMed ID: 15529633
[TBL] [Abstract][Full Text] [Related]
8. A randomized controlled trial to compare the effects of sulphonylurea gliclazide MR (modified release) and the DPP-4 inhibitor vildagliptin on glycemic variability and control measured by continuous glucose monitoring (CGM) in Brazilian women with type 2 diabetes.
Vianna AGD; Lacerda CS; Pechmann LM; Polesel MG; Marino EC; Faria-Neto JR
Diabetes Res Clin Pract; 2018 May; 139():357-365. PubMed ID: 29596951
[TBL] [Abstract][Full Text] [Related]
9. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study.
Filozof C; Gautier JF
Diabet Med; 2010 Mar; 27(3):318-26. PubMed ID: 20536495
[TBL] [Abstract][Full Text] [Related]
10. Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone.
Ristic S; Collober-Maugeais C; Pecher E; Cressier F
Diabet Med; 2006 Jul; 23(7):757-62. PubMed ID: 16842480
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of efficacy and tolerability of gliclazide and metformin combination: a multicentric study in patients with type 2 diabetes mellitus uncontrolled on monotherapy with sulfonylurea or metformin.
Pareek A; Chandurkar N; Zawar S; Agrawal N
Am J Ther; 2010; 17(6):559-65. PubMed ID: 20093927
[TBL] [Abstract][Full Text] [Related]
12. Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation.
Frey N; Laveille C; Paraire M; Francillard M; Holford NH; Jochemsen R
Br J Clin Pharmacol; 2003 Feb; 55(2):147-57. PubMed ID: 12580986
[TBL] [Abstract][Full Text] [Related]
13. The DIACOM study (effect of DosIng frequency of oral Antidiabetic agents on the COMpliance and biochemical control of type 2 diabetes).
Kardas P
Diabetes Obes Metab; 2005 Nov; 7(6):722-8. PubMed ID: 16219016
[TBL] [Abstract][Full Text] [Related]
14. [Medication of the month. Gliclazide modified release (Uni Diamicron)].
Scheen AJ
Rev Med Liege; 2003 Oct; 58(10):641-5. PubMed ID: 14677526
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of glimepiride/metformin sustained release once daily vs. glimepiride/metformin twice daily in patients with type 2 diabetes.
Hwang YC; Kang M; Ahn CW; Park JS; Baik SH; Chung DJ; Jang HC; Kim KA; Lee IK; Min KW; Nam M; Park TS; Son SM; Sung YA; Woo JT; Park KS; Lee MK
Int J Clin Pract; 2013 Mar; 67(3):236-43. PubMed ID: 23336668
[TBL] [Abstract][Full Text] [Related]
16. Glycemic control in patients with type 2 diabetes mellitus switched from twice-daily immediate-release metformin to a once-daily extended-release formulation.
Fujioka K; Pans M; Joyal S
Clin Ther; 2003 Feb; 25(2):515-29. PubMed ID: 12749511
[TBL] [Abstract][Full Text] [Related]
17. Maintenance of glycaemic control with the evening administration of a long acting sulphonylurea in male type 2 diabetic patients undertaking the Ramadan fast.
Zargar AH; Siraj M; Jawa AA; Hasan M; Mahtab H
Int J Clin Pract; 2010 Jul; 64(8):1090-4. PubMed ID: 20455956
[TBL] [Abstract][Full Text] [Related]
18. Acute and short-term administration of a sulfonylurea (gliclazide) increases pulsatile insulin secretion in type 2 diabetes.
Juhl CB; Pørksen N; Pincus SM; Hansen AP; Veldhuis JD; Schmitz O
Diabetes; 2001 Aug; 50(8):1778-84. PubMed ID: 11473038
[TBL] [Abstract][Full Text] [Related]
19. 24-hour glycemic profile in type 2 diabetic patients treated with gliclazide modified release once daily.
Guillausseau PJ; Greb W
Diabetes Metab; 2001 Apr; 27(2 Pt 1):133-7. PubMed ID: 11353879
[TBL] [Abstract][Full Text] [Related]
20. Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes.
Christiansen JS; Vaz JA; Metelko Z; Bogoev M; Dedov I
Diabetes Obes Metab; 2003 Nov; 5(6):446-54. PubMed ID: 14617231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
